Clinical efficacy of stem-cell therapy on diabetes mellitus: A systematic review and meta-analysis

This systematic literature review aims to compare the efficacy and safety of traditional and stem cell (SC) therapies for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus patients. The PubMed, SciELO, BVS, and Medline databases were searched, and 38 original articles were selected, which included 6...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplant immunology 2022-12, Vol.75, p.101740-101740, Article 101740
Hauptverfasser: Pires, Isabella Gouveia Santos, Silva e Souza, José Arthur, de Melo Bisneto, Abel Vieira, Passos, Xisto Sena, Carneiro, Cristiene Costa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This systematic literature review aims to compare the efficacy and safety of traditional and stem cell (SC) therapies for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus patients. The PubMed, SciELO, BVS, and Medline databases were searched, and 38 original articles were selected, which included 647 control cases and 654 treatments with three-, six- and twelve-month follow-ups of T1DM and T2DM patients. The efficacy of stem cell therapy was validated by comparing laboratory parameters such as fasting blood glucose and C-peptide levels before and after treatment. The REML model was chosen for random effects, and the inverse of variance was used for fixed effects. The statistical analysis was carried out using Bioestat 5.0 and STATA 16.0 software. All SC treatments significantly reduced the need for insulin following six and twelve months of treatment, whereas there was no significant decrease after three months. Fasting blood glucose and glycosylated hemoglobin levels were significantly reduced in all follow-ups with SC. In addition, SC treatment caused a significant increase in C-peptide levels. Bone marrow hematopoietic stem cell therapy produced better results than the conventional drug treatment for diabetes mellitus (semagglutide). The results with SC were significantly better, regardless of the follow-up period. Studies have proven cell therapy to be beneficial, safe, and effective. •The efficacy of stem cells (SC) was verified by comparing laboratory parameters.•All treatments with SC showed a significant reduction in the need for insulin.•The fasting blood glucose and glycosylated hemoglobin had a significant reduction.•C-peptide increased significantly after treatment with most of the researched SC.•In comparison with semagglutide the bone marrow SC therapy shown better results.
ISSN:0966-3274
1878-5492
DOI:10.1016/j.trim.2022.101740